|
1
|
Chen JG and Zhang SW: Liver cancer
epidemic in China: Past, present and future. Semin Cancer Biol.
21:59–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang H and Chen L: Tumor microenviroment
and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol.
28 (Suppl 1):S43–S48. 2013. View Article : Google Scholar
|
|
3
|
Liu T, Zhang S, Chen J, Jiang K, Zhang Q,
Guo K and Liu Y: The transcriptional profiling of glycogenes
associated with hepatocellular carcinoma metastasis. PLoS One.
9:e1079412014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ricciardi M, Zanotto M, Malpeli G, Bassi
G, Perbellini O, Chilosi M, Bifari F and Krampera M:
Epithelial-to-mesenchymal transition (EMT) induced by inflammatory
priming elicits mesenchymal stromal cell-like immune-modulatory
properties in cancer cells. Br J Cancer. 112:1067–1075. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pawitan Y, Yin L, Setiawan A, Auer G,
Smedby KE and Czene K: Distinct effects of anti-inflammatory and
anti-thrombotic drugs on cancer characteristics at diagnosis. Eur J
Cancer. 51:751–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Briso EM, Guinea-Viniegra J, Bakiri L,
Rogon Z, Petzelbauer P, Eils R, Wolf R, Rincón M, Angel P and
Wagner EF: Inflammation-mediated skin tumorigenesis induced by
epidermal c-Fos. Genes Dev. 27:1959–1973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feng J, Chen X, Wang Y, Du Y, Sun Q, Zang
W and Zhao G: Myricetin inhibits proliferation and induces
apoptosis and cell cycle arrest in gastric cancer cells. Mol Cell
Biochem. 408:163–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baldo BA and Pham NH: Adverse reactions to
targeted and non-targeted chemotherapeutic drugs with emphasis on
hypersensitivity responses and the invasive metastatic switch.
Cancer Metastasis Rev. 32:723–761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tong Y, Zhou XM, Wang SJ, Yang Y and Cao
YL: Analgesic activity of myricetin isolated from Myrica rubra
Sieb. et Zucc. leaves. Arch Pharm Res. 32:527–533. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan X, Liu Y, Hua X, Deng X, Sun P, Yu C,
Chen L, Yu S, Liu S and Pang H: Myricetin ameliorates the symptoms
of collagen-induced arthritis in mice by inhibiting cathepsin K
activity. Immunopharmacol Immunotoxicol. 37:513–519. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kandasamy N and Ashokkumar N: Protective
effect of bioflavonoid myricetin enhances carbohydrate metabolic
enzymes and insulin signaling molecules in streptozotocin-cadmium
induced diabetic nephrotoxic rats. Toxicol Appl Pharmacol.
279:173–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jose J, Dhanya AT, Haridas KR, Sumesh
Kumar TM, Jayaraman S, Variyar EJ and Sudhakaran S: Structural
characterization of a novel derivative of myricetin from Mimosa
pudica as an anti-proliferative agent for the treatment of cancer.
Biomed Pharmacother. 84:1067–1077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Semwal DK, Semwal RB, Combrinck S and
Viljoen A: Myricetin: A dietary molecule with diverse biological
activities. Nutrients. 8:902016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shih YW, Wu PF, Lee YC, Shi MD and Chiang
TA: Myricetin suppresses invasion and migration of human lung
adenocarcinoma A549 cells: Possible mediation by blocking the ERK
signaling pathway. J Agric Food Chem. 57:3490–3499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumamoto T, Fujii M and Hou DX: Myricetin
directly targets JAK1 to inhibit cell transformation. Cancer Lett.
275:17–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seydi E, Rasekh HR, Salimi A, Mohsenifar Z
and Pourahmad J: Myricetin selectively induces apoptosis on
cancerous hepatocytes by directly targeting their mitochondria.
Basic Clin Pharmacol Toxicol. 119:249–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY,
Chen J and Xue Q: New human hepatocellular carcinoma (HCC) cell
line with highly metastatic potential (MHCC97) and its expressions
of the factors associated with metastasis. Br J Cancer. 81:814–821.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Meth. 25:402–408. 2001. View Article : Google Scholar
|
|
19
|
Zhao H, Jiao Y and Zhang Z: Deguelin
inhibits the migration and invasion of lung cancer A549 and H460
cells via regulating actin cytoskeleton rearrangement. Int J Clin
Exp Pathol. 8:15582–15590. 2015.PubMed/NCBI
|
|
20
|
Chen L, Chan TH, Yuan YF, Hu L, Huang J,
Ma S, Wang J, Dong SS, Tang KH, Xie D, et al: CHD1L promotes
hepatocellular carcinoma progression and metastasis in mice and is
associated with these processes in human patients. J Clin Invest.
120:1178–1191. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin Z, Li W, Zhang H, Wu W, Peng Y, Zeng
Y, Wan Y, Wang J and Ouyang N: CCL18/PITPNM3 enhances migration,
invasion, and EMT through the NF-κB signaling pathway in
hepatocellular carcinoma. Tumour Biol. 37:3461–3468. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ko CH, Shen SC, Lee TJ and Chen YC:
Myricetin inhibits matrix metalloproteinase 2 protein expression
and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther.
4:281–290. 2005.PubMed/NCBI
|
|
23
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung HY, Fattet L and Yang J: Molecular
pathways: Linking tumor microenvironment to epithelial-mesenchymal
transition in metastasis. Clin Cancer Res. 21:962–968. 2015.
View Article : Google Scholar : PubMed/NCBI
|
